OTCMKTS:BSEM BioStem Technologies Q3 2024 Earnings Report $14.69 +0.16 (+1.11%) As of 03:59 PM Eastern Earnings History BioStem Technologies EPS ResultsActual EPS$0.32Consensus EPS $0.31Beat/MissBeat by +$0.01One Year Ago EPSN/ABioStem Technologies Revenue ResultsActual Revenue$82.56 millionExpected Revenue$78.22 millionBeat/MissBeat by +$4.34 millionYoY Revenue GrowthN/ABioStem Technologies Announcement DetailsQuarterQ3 2024Date11/12/2024TimeBefore Market OpensConference Call DateTuesday, November 12, 2024Conference Call Time4:30PM ETConference Call ResourcesConference Call AudioConference Call TranscriptPress Release (8-K)Earnings HistoryCompany ProfilePowered by BioStem Technologies Q3 2024 Earnings Call TranscriptProvided by QuartrNovember 12, 2024 ShareLink copied to clipboard.There are 6 speakers on the call. Operator00:00:00Thank you for standing by. My name is Rebecca, and I will be your conference operator today. At this time, I would like to welcome everyone to the BioStim Technologies Third Quarter Results Webcast Call. All lines have been placed on mute to prevent any background noise. After the speakers' remarks, there will be a question and answer session. Operator00:00:33Thank you. I would now like to turn the call over to Adam Holdsworth, Managing Director of Investor Relations. Please go ahead. Speaker 100:00:44Good afternoon, everyone, and thank you for joining our conference call to discuss BioStim's Q3 2024 financial results and corporate highlights. Leading the call today will be Jason Manashevsky, the company's Founder and Chief Executive Officer and Mike Fortunato, the company's Chief Financial Officer. Before we begin, I'd like to remind everyone that our remarks today may contain forward looking statements based on the current expectations of management, which involve inherent risks and uncertainties that could cause actual results to differ materially from those indicated. These risks are described in the company's filings with the over the counter market. We're cautioned not to place undue reliance on any forward looking statements, which speak only as of the date made and may change at any time. Speaker 100:01:31While we may update or revise these statements from time to time, the company undertakes no commitment to do so unless required by typical securities laws. This call also includes references to certain financial measures that are not calculated in accordance with generally accepted accounting principles or GAAP. We generally refer to these as non GAAP financial measures. Reconciliations of these non GAAP financial measures to the most comparable GAAP measures are available in the company's press release on the Investor Relations section of BioSem's website. With that, I'm now pleased to turn the call over to Jason Monachevsky. Speaker 200:02:08Thank you, Adam, and thank you all for joining us today. I'm pleased to report that BioStim Technologies has achieved another milestone, marking our 3rd consecutive quarter of record setting growth. In Q3 of 2024, we posted revenue of $82,600,000 adjusted EBITDA of $9,900,000 and our cash position improved to $14,600,000 establishing a new revenue high for the company and demonstrating our robust financial performance. For the 1st 9 months of this year, we've generated $199,000,000 in net revenue, highlighting our continued momentum and resilience in the market. Our success this quarter is a testament to the strength of our portfolio of skin substitutes, especially our Amniorap 2 allograft powered by our patented biorepane technology. Speaker 200:02:55This innovative technology is driving strong commercial performance across a wide range of non acute segments. Our gross margin remains solid at 95%, reflecting our commitment to operational excellence and the efficiency of our manufacturing processes. I want to take this moment to recognize the dedication of the entire BioSEM team, your commitment to our vision and the honor you bring to the gift of donation are what drives these outstanding results. As part of our efforts to ensure patient access to high quality life changing products, we've been actively engaging with CMS, congressional leaders and industry partners to advocate for fair and effective Medicare reimbursement policies. We recognize that certain players have caused over utilization within the Medicare reimbursement system, impacting policy and patient access. Speaker 200:03:47Our goal is to help shape our reimbursement landscape that not only supports ethical practices, but also ensures that millions of Medicare beneficiaries have access to vital treatments. BioStim remains at the forefront of this conversation, collaborating with government and industry leaders to support responsible patient centered policy solutions. Turning to partnerships, I'd like to extend my gratitude to our commercialization partner, Venture Medical. Their role has been instrumental in our growth journey as they led the nationwide launch of Amnurant2 in Q4 of 2023 and are now preparing for Vendaj AC's launch in Q4 of 2024. Venture Medical is a key commercialization and marketing partner and we're thrilled to work side by side with them once again with Vendaj AC, which recently had a national ASP published for Q4 2024, allowing reimbursement across all MAC regions. Speaker 200:04:43Early in the quarter, we received IRB approval for 2 major clinical studies on non healing diabetic foot ulcers. These approvals are essential milestones in our clinical journey and support our commitment to rigorous and tactical research. We recently enrolled our first patients in 2 randomized controlled clinical trials this quarter evaluating our bioretaine allografts. We anticipate an early readout of these results from these studies by mid-twenty 25 and final results in early 2026, providing us with clinical data that will strengthen our clinical approach, broaden our payer coverage base and support expanded access to our innovative products. Additionally, we're in the final stages of designing a study protocol for venous leg ulcers with timelines to be communicated once finalized. Speaker 200:05:30We recently reported positive results from a retrospective data study comparing our BioRetain Allografts to the standard of care for diabetic foot ulcers, underscoring our commitment to advancing clinical data on our products. In October, these findings were published in an International Moon Journal providing valuable peer review validation of our technology's effectiveness. This achievement further reinforces BioSyn's standing as a leader in research backed innovation. In support of our equity capital market strategy, we filed our Form 10 on September 27 with the SEC and submitted an application for uplifting to NASDAQ at the same time. We are currently working through our initial SEC review comments and expect to submit a formal response in Q4, along with amended Form 10. Speaker 200:06:17Uplifting to a national exchange and becoming fully reporting with the SEC is the strategic commitment to enhance BioStim's visibility and provide wider accessibility to a broader investor base. As we look to the remainder of 2024 and beyond, BioSTEM is well positioned for continued growth and innovation. Despite industry challenges, our strong foundation evidenced by our robust portfolio and effective partnerships positions us to adapt and grow. We are confident that our strategic initiatives, groundbreaking products and dedicated team provide a solid foundation for future success. Looking ahead, we are optimistic about our upcoming clinical trial results and the potential for broadening our market access, which could provide further clinical validation of our products, superiority and drive broader payer coverage and adoption of BioSens allograft. Speaker 200:07:10These initiatives have the potential to diversify and expand our product offerings, positioning us on a strong trajectory to deliver value for our shareholders, expand our market presence and improve patient outcomes with our innovative solutions. Thank you to our shareholders, Venture Medical and our team members for their ongoing trust, dedication and support as we work to bring transformative solutions across the continuum of care to patients and providers. With that, I'll now hand the call over to Mike Fortunato, who will provide a detailed review of our financial results for Q3 2024. Speaker 300:07:46Thank you, Jason, and good afternoon to everyone. We appreciate you being here with us today. I am pleased to share BioStim's Q3 2024 financial results, which highlight continued strong growth and significant milestones for the company. 2024 has been a transformative year for BioStim. When we compare this quarter to the same period last year, the progress we made is significant and we're excited to share the results. Speaker 300:08:09For the Q3 of 2024, net revenue reached a record $82,600,000 reflecting an increase of $79,000,000 compared to the same period in 2023. This growth is primarily driven by continued strong demand for mbioRAP2, which has been performing exceptionally well across a range of patient applications. Our gross profit for Q3 was $78,300,000 or 95% of net revenue compared to $3,200,000 or 91% of net revenue in the prior year same period. This represents an increase of $75,100,000 driven by robust sales growth of Aviorap 2 and highlights our manufacturing and operational efficiencies. Operating expenses for Q3 2024 was 69,000,000 dollars up from $4,500,000 in the same period last year, an increase of $64,500,000 This increase was largely due to workforce expansion, higher bona fide service fees associated with our distributor agreements for Indorep 2 and increased share based compensation as we continue to scale our operations. Speaker 300:09:12For the 9 month period ended September 30, 2024, we reported net revenue of $199,000,000 an increase of approximately $194,000,000 compared to the same period in 2023. The majority of this growth was driven by amniorap2, which continues to experience strong market demand. Our gross profit for the 1st 9 months was $188,700,000 or 95 percent of net revenue compared to 4 point $5,000,000 or 88 percent of net revenue for the same period last year. This increase of $184,200,000 reflects higher sales volumes of Amneal RAP2 and improved manufacturing and operational efficiencies. Operating expenses for the 1st 9 months of 2024 were $166,000,000 an increase of $154,000,000 from the same period last year. Speaker 300:10:00This increase was driven by continued investments in scaling our operations, including workforce growth, higher bona fide service fees related to Amniorap 2 distribution and increases in share based compensation. We are pleased to report that we have achieved positive GAAP net income for the 3rd consecutive quarter. Net income and adjusted EBITDA for the quarter was $6,800,000 $9,900,000 respectively. These results demonstrate our ability to continue to scale the business to meet strong revenue growth while remaining profitable. In addition, our cash balance has increased from $6,800,000 from the previous quarter to $14,600,000 in the current quarter, an increase of $7,800,000 Regarding income taxes payable on the balance sheet, management has estimated income tax expense of $2,300,000 for the Q3 $5,800,000 year to date September 30, 2024, heading the completion of the Internal Revenue Code Section 382 study currently underway. Speaker 300:10:58This study will determine if there are any limitations on the timing of using previously generated net operating losses to offset current year taxable income. Although these amounts are recorded as income tax payable, management expects that most, if not all of this estimate will be offset by the NOLs by December 31, 2024. As we look to the remainder of 2024, we are confident that these strong financial results paired with the successful execution of our strategic initiatives position BioStim for continued success. We will continue to drive growth, enhance profitability and maximize value for our shareholders. I'll now turn over the call to Jason for closing remarks. Speaker 200:11:36Thank you, Mike. As he just outlined, this quarter marks several significant milestones that have driven BioSense growth and demonstrated exceptional financial performance. With Q3 revenue reaching a new high of $82,600,000 and an adjusted EBITDA of $9,900,000 and a strengthened cash position of $14,600,000 Our results underscore the effectiveness of our strategy and the resilience of our team. I'd like to address some updates on coverage and payment policies for Skin Subsitutes, specifically for our products. Last Friday, the Centers For Medicare and Medicaid Services, CMS, finalized their pricing methodology for skin substitutes in a physician office space or non acute segment for 2025. Speaker 200:12:21CMS confirmed they will continue with ASP plus 6 as the pricing model. This decision bolsters our confidence and pricing stability for the coming year and ensures that BioSyn can maintain its current pricing and commercial strategy as we continue to scale our business. Now regarding the coverage policy, we're actively engaging with CMS, Congress, the MACs and industry leaders to address the proposed LCD. This proposal could impact hundreds of essential products, including ours, potentially limiting access for Medicare beneficiaries who rely on these treatments. Our goal is to advocate for a well founded and equitable coverage policy that balances ethical practice with patient safety. Speaker 200:13:03While we acknowledge over utilization by some parties in the market, we believe a more rigorous approach is needed, one that doesn't place patient access at risk. BioStent remains at the forefront of this effort, collaborating closely with government and industry stakeholders to support policies that responsibly expand patient access to life changing products. Our efforts, which include engaging closely with Capitol Hill leaders, aim to secure better, more equitable coverage for skin substitutes benefiting both the Medicare beneficiaries and BioStem. October marked the kickoff of a pivotal clinical trial on diabetic foot ulcers comparing our treatments to the standard of care. This study involving 60 patients across 10 sites is essential to building evidence of the clinical superiority of BioStim's products. Speaker 200:13:52Alongside an upcoming study focused on venous leg ulcers, these trials are key to demonstrating BioStim's value and expanding payer coverage across commercial plans, Medicare Advantage and Medicaid. In addition, we announced groundbreaking results in October from a retrospective study on diabetic foot ulcer wound closure, underscoring the clinical superiority of our bioreteum processed placental membrane over the standard of care published in the International Loon Journal. These results highlight the potential for biorutane to address significant gaps in the DFU market, often involving challenging treatment resistant wounds. This publication strengthens Biofins clinical credibility and supports our strategy to expand payer coverage and commercial traction across Medicare, Medicare Advantage and Medicaid and other payer channels. We are excited about the strategic value this study brings as it reinforces BioStem's position as a leader in providing effective evidence based solutions for chronic wound care. Speaker 200:14:54We remain optimistic that the current proposed LCD will not get implemented in 2025 without amendments being implemented, which could favor BioStem. Looking forward, we're confident that these trials will provide additional clinical validation for our commercial products, efficacy, driving expanded payer coverage and broader adoption of BioSymes allografts. Pivoting to the equity capital markets front, we made a significant advancement in September by filing a Form 10 with the SEC on 27th and simultaneously submitting our NASDAQ uplisting application. We are now working through our initial SEC review comments and plan to submit a formal response along with an amended Form 10 in Q4. This uplifting to a national exchange and transition to fully reporting status are key milestones in BioSom's strategy aimed at enhancing our credibility, broadening our investor reach and increasing access to capital, essential drivers of a long term shareholder value as we continue to execute on our growth initiatives. Speaker 200:15:55In closing, as we enter the Q4, we remain optimistic about BioSyn's continued growth and the significant milestones on the horizon. With the recent nationwide launch of Bendaj AC and established reimbursement across all MAC regions, we're well positioned to see strong revenue contributions from this product. This quarter marks our 3rd consecutive record of growth and we're excited about the initiatives underway that have the potential to diversify and expand our product offerings. As we continue to advance our strategic priorities, we're confident that BioSim is on a strong trajectory to deliver value to our shareholders, expand our market presence and improve patient outcomes with innovative solutions. We look forward to keeping you up to date on our progress and I appreciate your continued support as we work towards greater success. Speaker 200:16:43Thank you. And we'll now open the call for questions. Operator00:17:12Your first question comes from the line of Kevin Bennett, an individual investor. Speaker 400:17:19Good evening, guys. Good job on the quarter there. Just had a few questions, I guess. The distribution cost maybe is like my biggest thing that I have. I don't know if we could restructure that, maybe give them like an exclusive deal with us or something, maybe more profit for us and then give them a security of having all of our business. Speaker 400:17:432nd question is the I'm assuming this is like a cream that you put on diabetic wounds. Is it actually possible to have this like an airborne, like spray thing, like burn victims? Would that actually work on a product like that? And then my third question is on the uplifting, the share structure, what will happen with the share structure? I know we're like at about $16,000,000 $11,000,000 out $5,000,000 restricted. Speaker 400:18:14Just curious what will happen with that. Like I say, that's all the questions I have. I appreciate your work. Speaker 200:18:23Thanks, Kevin, for being a long term shareholder and really appreciate the questions. 1st and foremost on the distribution side with Venture Medical, right now we're continuing to kind of work through that team and they've done an amazing job of expanding access to our product across all the MAC regions. I think right now we're looking at continuing that type of relationship in the near term. And to kind of compare it to, I guess, maybe competitors, if we were to internalize this type of sales force from a W2 perspective, I think we would see similar costs associated with this marketplace in getting product out into the marketplace. On the second question in regards to a cream, actually our products are considered what they call tissue allografts. Speaker 200:19:14So we actually harvest a piece of tissue off of the placenta. And so it's like a sheet like format that's laid into the wound bed across the wound and it acts as a barrier or cover for these chronic type wounds, so diabetic foot ulcers, pressure ulcers and venous leg ulcers? And then 3rd, in regards to the capital structure excuse me, the equity capital structure, right now, I believe there's about 16 and so 1,000,000 shares outstanding in common stock. That would be kind of ultimately move from OTC up to NASDAQ. And then any of the warrants and options that are outstanding would also move up to NASDAQ. Speaker 200:19:59So currently, that's kind of the plan with the direct listing. Speaker 400:20:06Okay. Thanks a lot. Speaker 200:20:08No problem, sir. Operator00:20:17Your next question comes from the line of Paige Taggart with APT Capital. Hey, Jason, congrats on another record quarter. Just a quick question, if you could provide some more color around distribution channel with Venture Medical, I guess specifically the sales cycle would be helpful for me. Thanks. Speaker 200:20:39Yes. Thanks, Dave. So just kind of get a little bit more color to kind of how we fulfill and manage the pipeline with Venture Medical. So Venture Medical on a daily basis is ordering product from us and we are shipping it out on a daily basis. It's very lean and FIFO type arrangement with that organization. Speaker 200:21:02And then secondly, they're continuing to have weekly conversations with us about what is the demand pipeline looking like and we're continuing to kind of monitor from a manufacturing perspective how quickly we need to increase production in specific sizes and that's associated with their robust platform called Venture 1View that they utilize with their downstream customers to ultimately kind of see where these types of wounds are going. In this process, typically these wounds or these providers ultimately run what's called an IVR, insurance verification request, And they can see kind of where and what size the wound is and can kind of get an idea of, okay, where is the wound going from an initial size and then kind of as the wound gets closer to closure. So that allows us to have a little bit more insight on product needs and kind of product production. So thanks for your question. Operator00:22:04Thank you. Your next question comes from the line of Ernest Watts with Watts Associates. Speaker 500:22:14I appreciate the progress that you're showing and the comments that you made today. You mentioned in the release that build up costs were significant and apparently much more significant than the Q2. Could you give a comment on roughly what they were in each of the 2 quarters, please? Speaker 200:22:39Ernest, could you clarify your question a little bit? When you say build up costs, what do you mean? Speaker 500:22:46It costs money to get your product out into the field and you have to have people to do that, those people are hired before the actual revenues come in. So I'm referring to costs that precede revenues. Speaker 200:23:09Got it. So, yes, as mentioned on the income statement, notice there's obviously elements of SG and A. Obviously, the biggest one is bona fide services. Those services are specific to Venture Medical being out into the field and commercializing our product. And those are a direct correlation to the revenue, top line revenues specifically. Speaker 200:23:34So as top line revenue increases, those specific bonafide services, which make up a large portion of the SG and A, kind of incrementally shift in that direction. Speaker 500:23:48Could you give a rough figure for the 2 each of the 2 quarters? Speaker 300:23:58Go ahead, I can help with that, Jason, if you want. So sales and marketing so Bonafide service fees are included in sales and marketing expenses for a few for Q3, they were $65,100,000 for 3 months. And for the previous quarter, I want to say they were around 50, around mid-50s, dollars 50 something million. And again, that's indirect. Those costs go up or down with in relation to revenue. Speaker 300:24:24So as revenue increases, you can expect those bonafide service fees and sales and marketing expenses to go up. Does that help? Speaker 100:24:36That's it. Speaker 500:24:38Okay. Thank you Speaker 200:24:40for your questions. Operator00:24:46I will now turn the call back over to Jason Monachevsky for closing remarks. Speaker 200:24:52Well, thanks everyone for joining the call today. We had an amazing Q3 results And I want to thank everybody, specifically all of the BioSEM team members as well as the folks at Venture Medical for all the amazing success that we've had in Q3 of this year and looking forward to sharing our results for the end of the year and Q4 results with you all in the near term. Thank you everyone and have a great night. Operator00:25:19Ladies and gentlemen, that concludes today's call. Thank you all for joining. You may now disconnect.Read morePowered by Conference Call Audio Live Call not available Earnings Conference CallBioStem Technologies Q3 202400:00 / 00:00Speed:1x1.25x1.5x2x Earnings DocumentsPress Release(8-K) BioStem Technologies Earnings HeadlinesShort Interest in BioStem Technologies, Inc. (OTCMKTS:BSEM) Expands By 20.5%April 22 at 3:49 AM | americanbankingnews.comBioStem Technologies to Present at the Centri Capital ConferenceApril 21, 2025 | globenewswire.comReal Americans Don’t Wait on Wall Street’s Next MoveWhat's happening in the markets right now should concern every freedom-loving American who's worked hard and saved smart. Your 401(k) doesn't deserve to be dragged through the mud by tariffs, trade wars, reckless spending, and political standoffs. And you don't have to stand by while Wall Street plays roulette with your future.April 25, 2025 | Premier Gold Co (Ad)BSEM Posts Record Revenue and ProfitApril 15, 2025 | msn.comBioStem Technologies, Inc. (BSEM) Q4 2024 Earnings Call TranscriptApril 14, 2025 | seekingalpha.comBioStem Technologies Reports Record Preliminary Fourth-Quarter Net Revenue of $102.9 Million and Preliminary Full-Year 2024 Revenue of $301.8 MillionApril 14, 2025 | globenewswire.comSee More BioStem Technologies Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like BioStem Technologies? Sign up for Earnings360's daily newsletter to receive timely earnings updates on BioStem Technologies and other key companies, straight to your email. Email Address About BioStem TechnologiesBioStem Technologies (OTCMKTS:BSEM), a life sciences corporation, focuses on discovering, developing, and producing pharmaceutical and regenerative medicine products and services. It develops various biologic stem cell based alternative products, as a treatment for ailments, such as joint pain, tendon and ligament injuries, neurodegenerative, and autoimmune diseases. The company is also engages in the repackaging and distribution of active pharmaceutical ingredients and other pharmaceutical compounding supplies; and develops and markets nutraceutical products under the Dr. Dave's Best and Nesvik Organics brands, as well as other non-proprietary products in the United States and internationally. The company sells products through e-commerce platforms. BioStem Technologies, Inc. was incorporated in 2006 and is based in Pompano Beach, Florida.View BioStem Technologies ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Market Anticipation Builds: Joby Stock Climbs Ahead of EarningsIs Intuitive Surgical a Buy After Volatile Reaction to Earnings?Seismic Shift at Intel: Massive Layoffs Precede Crucial EarningsRocket Lab Lands New Contract, Builds Momentum Ahead of EarningsAmazon's Earnings Could Fuel a Rapid Breakout Tesla Earnings Miss, But Musk Refocuses and Bulls ReactQualcomm’s Range Narrows Ahead of Earnings as Bulls Step In Upcoming Earnings Cadence Design Systems (4/28/2025)Welltower (4/28/2025)Waste Management (4/28/2025)AstraZeneca (4/29/2025)Booking (4/29/2025)DoorDash (4/29/2025)Honeywell International (4/29/2025)Mondelez International (4/29/2025)PayPal (4/29/2025)Regeneron Pharmaceuticals (4/29/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
There are 6 speakers on the call. Operator00:00:00Thank you for standing by. My name is Rebecca, and I will be your conference operator today. At this time, I would like to welcome everyone to the BioStim Technologies Third Quarter Results Webcast Call. All lines have been placed on mute to prevent any background noise. After the speakers' remarks, there will be a question and answer session. Operator00:00:33Thank you. I would now like to turn the call over to Adam Holdsworth, Managing Director of Investor Relations. Please go ahead. Speaker 100:00:44Good afternoon, everyone, and thank you for joining our conference call to discuss BioStim's Q3 2024 financial results and corporate highlights. Leading the call today will be Jason Manashevsky, the company's Founder and Chief Executive Officer and Mike Fortunato, the company's Chief Financial Officer. Before we begin, I'd like to remind everyone that our remarks today may contain forward looking statements based on the current expectations of management, which involve inherent risks and uncertainties that could cause actual results to differ materially from those indicated. These risks are described in the company's filings with the over the counter market. We're cautioned not to place undue reliance on any forward looking statements, which speak only as of the date made and may change at any time. Speaker 100:01:31While we may update or revise these statements from time to time, the company undertakes no commitment to do so unless required by typical securities laws. This call also includes references to certain financial measures that are not calculated in accordance with generally accepted accounting principles or GAAP. We generally refer to these as non GAAP financial measures. Reconciliations of these non GAAP financial measures to the most comparable GAAP measures are available in the company's press release on the Investor Relations section of BioSem's website. With that, I'm now pleased to turn the call over to Jason Monachevsky. Speaker 200:02:08Thank you, Adam, and thank you all for joining us today. I'm pleased to report that BioStim Technologies has achieved another milestone, marking our 3rd consecutive quarter of record setting growth. In Q3 of 2024, we posted revenue of $82,600,000 adjusted EBITDA of $9,900,000 and our cash position improved to $14,600,000 establishing a new revenue high for the company and demonstrating our robust financial performance. For the 1st 9 months of this year, we've generated $199,000,000 in net revenue, highlighting our continued momentum and resilience in the market. Our success this quarter is a testament to the strength of our portfolio of skin substitutes, especially our Amniorap 2 allograft powered by our patented biorepane technology. Speaker 200:02:55This innovative technology is driving strong commercial performance across a wide range of non acute segments. Our gross margin remains solid at 95%, reflecting our commitment to operational excellence and the efficiency of our manufacturing processes. I want to take this moment to recognize the dedication of the entire BioSEM team, your commitment to our vision and the honor you bring to the gift of donation are what drives these outstanding results. As part of our efforts to ensure patient access to high quality life changing products, we've been actively engaging with CMS, congressional leaders and industry partners to advocate for fair and effective Medicare reimbursement policies. We recognize that certain players have caused over utilization within the Medicare reimbursement system, impacting policy and patient access. Speaker 200:03:47Our goal is to help shape our reimbursement landscape that not only supports ethical practices, but also ensures that millions of Medicare beneficiaries have access to vital treatments. BioStim remains at the forefront of this conversation, collaborating with government and industry leaders to support responsible patient centered policy solutions. Turning to partnerships, I'd like to extend my gratitude to our commercialization partner, Venture Medical. Their role has been instrumental in our growth journey as they led the nationwide launch of Amnurant2 in Q4 of 2023 and are now preparing for Vendaj AC's launch in Q4 of 2024. Venture Medical is a key commercialization and marketing partner and we're thrilled to work side by side with them once again with Vendaj AC, which recently had a national ASP published for Q4 2024, allowing reimbursement across all MAC regions. Speaker 200:04:43Early in the quarter, we received IRB approval for 2 major clinical studies on non healing diabetic foot ulcers. These approvals are essential milestones in our clinical journey and support our commitment to rigorous and tactical research. We recently enrolled our first patients in 2 randomized controlled clinical trials this quarter evaluating our bioretaine allografts. We anticipate an early readout of these results from these studies by mid-twenty 25 and final results in early 2026, providing us with clinical data that will strengthen our clinical approach, broaden our payer coverage base and support expanded access to our innovative products. Additionally, we're in the final stages of designing a study protocol for venous leg ulcers with timelines to be communicated once finalized. Speaker 200:05:30We recently reported positive results from a retrospective data study comparing our BioRetain Allografts to the standard of care for diabetic foot ulcers, underscoring our commitment to advancing clinical data on our products. In October, these findings were published in an International Moon Journal providing valuable peer review validation of our technology's effectiveness. This achievement further reinforces BioSyn's standing as a leader in research backed innovation. In support of our equity capital market strategy, we filed our Form 10 on September 27 with the SEC and submitted an application for uplifting to NASDAQ at the same time. We are currently working through our initial SEC review comments and expect to submit a formal response in Q4, along with amended Form 10. Speaker 200:06:17Uplifting to a national exchange and becoming fully reporting with the SEC is the strategic commitment to enhance BioStim's visibility and provide wider accessibility to a broader investor base. As we look to the remainder of 2024 and beyond, BioSTEM is well positioned for continued growth and innovation. Despite industry challenges, our strong foundation evidenced by our robust portfolio and effective partnerships positions us to adapt and grow. We are confident that our strategic initiatives, groundbreaking products and dedicated team provide a solid foundation for future success. Looking ahead, we are optimistic about our upcoming clinical trial results and the potential for broadening our market access, which could provide further clinical validation of our products, superiority and drive broader payer coverage and adoption of BioSens allograft. Speaker 200:07:10These initiatives have the potential to diversify and expand our product offerings, positioning us on a strong trajectory to deliver value for our shareholders, expand our market presence and improve patient outcomes with our innovative solutions. Thank you to our shareholders, Venture Medical and our team members for their ongoing trust, dedication and support as we work to bring transformative solutions across the continuum of care to patients and providers. With that, I'll now hand the call over to Mike Fortunato, who will provide a detailed review of our financial results for Q3 2024. Speaker 300:07:46Thank you, Jason, and good afternoon to everyone. We appreciate you being here with us today. I am pleased to share BioStim's Q3 2024 financial results, which highlight continued strong growth and significant milestones for the company. 2024 has been a transformative year for BioStim. When we compare this quarter to the same period last year, the progress we made is significant and we're excited to share the results. Speaker 300:08:09For the Q3 of 2024, net revenue reached a record $82,600,000 reflecting an increase of $79,000,000 compared to the same period in 2023. This growth is primarily driven by continued strong demand for mbioRAP2, which has been performing exceptionally well across a range of patient applications. Our gross profit for Q3 was $78,300,000 or 95% of net revenue compared to $3,200,000 or 91% of net revenue in the prior year same period. This represents an increase of $75,100,000 driven by robust sales growth of Aviorap 2 and highlights our manufacturing and operational efficiencies. Operating expenses for Q3 2024 was 69,000,000 dollars up from $4,500,000 in the same period last year, an increase of $64,500,000 This increase was largely due to workforce expansion, higher bona fide service fees associated with our distributor agreements for Indorep 2 and increased share based compensation as we continue to scale our operations. Speaker 300:09:12For the 9 month period ended September 30, 2024, we reported net revenue of $199,000,000 an increase of approximately $194,000,000 compared to the same period in 2023. The majority of this growth was driven by amniorap2, which continues to experience strong market demand. Our gross profit for the 1st 9 months was $188,700,000 or 95 percent of net revenue compared to 4 point $5,000,000 or 88 percent of net revenue for the same period last year. This increase of $184,200,000 reflects higher sales volumes of Amneal RAP2 and improved manufacturing and operational efficiencies. Operating expenses for the 1st 9 months of 2024 were $166,000,000 an increase of $154,000,000 from the same period last year. Speaker 300:10:00This increase was driven by continued investments in scaling our operations, including workforce growth, higher bona fide service fees related to Amniorap 2 distribution and increases in share based compensation. We are pleased to report that we have achieved positive GAAP net income for the 3rd consecutive quarter. Net income and adjusted EBITDA for the quarter was $6,800,000 $9,900,000 respectively. These results demonstrate our ability to continue to scale the business to meet strong revenue growth while remaining profitable. In addition, our cash balance has increased from $6,800,000 from the previous quarter to $14,600,000 in the current quarter, an increase of $7,800,000 Regarding income taxes payable on the balance sheet, management has estimated income tax expense of $2,300,000 for the Q3 $5,800,000 year to date September 30, 2024, heading the completion of the Internal Revenue Code Section 382 study currently underway. Speaker 300:10:58This study will determine if there are any limitations on the timing of using previously generated net operating losses to offset current year taxable income. Although these amounts are recorded as income tax payable, management expects that most, if not all of this estimate will be offset by the NOLs by December 31, 2024. As we look to the remainder of 2024, we are confident that these strong financial results paired with the successful execution of our strategic initiatives position BioStim for continued success. We will continue to drive growth, enhance profitability and maximize value for our shareholders. I'll now turn over the call to Jason for closing remarks. Speaker 200:11:36Thank you, Mike. As he just outlined, this quarter marks several significant milestones that have driven BioSense growth and demonstrated exceptional financial performance. With Q3 revenue reaching a new high of $82,600,000 and an adjusted EBITDA of $9,900,000 and a strengthened cash position of $14,600,000 Our results underscore the effectiveness of our strategy and the resilience of our team. I'd like to address some updates on coverage and payment policies for Skin Subsitutes, specifically for our products. Last Friday, the Centers For Medicare and Medicaid Services, CMS, finalized their pricing methodology for skin substitutes in a physician office space or non acute segment for 2025. Speaker 200:12:21CMS confirmed they will continue with ASP plus 6 as the pricing model. This decision bolsters our confidence and pricing stability for the coming year and ensures that BioSyn can maintain its current pricing and commercial strategy as we continue to scale our business. Now regarding the coverage policy, we're actively engaging with CMS, Congress, the MACs and industry leaders to address the proposed LCD. This proposal could impact hundreds of essential products, including ours, potentially limiting access for Medicare beneficiaries who rely on these treatments. Our goal is to advocate for a well founded and equitable coverage policy that balances ethical practice with patient safety. Speaker 200:13:03While we acknowledge over utilization by some parties in the market, we believe a more rigorous approach is needed, one that doesn't place patient access at risk. BioStent remains at the forefront of this effort, collaborating closely with government and industry stakeholders to support policies that responsibly expand patient access to life changing products. Our efforts, which include engaging closely with Capitol Hill leaders, aim to secure better, more equitable coverage for skin substitutes benefiting both the Medicare beneficiaries and BioStem. October marked the kickoff of a pivotal clinical trial on diabetic foot ulcers comparing our treatments to the standard of care. This study involving 60 patients across 10 sites is essential to building evidence of the clinical superiority of BioStim's products. Speaker 200:13:52Alongside an upcoming study focused on venous leg ulcers, these trials are key to demonstrating BioStim's value and expanding payer coverage across commercial plans, Medicare Advantage and Medicaid. In addition, we announced groundbreaking results in October from a retrospective study on diabetic foot ulcer wound closure, underscoring the clinical superiority of our bioreteum processed placental membrane over the standard of care published in the International Loon Journal. These results highlight the potential for biorutane to address significant gaps in the DFU market, often involving challenging treatment resistant wounds. This publication strengthens Biofins clinical credibility and supports our strategy to expand payer coverage and commercial traction across Medicare, Medicare Advantage and Medicaid and other payer channels. We are excited about the strategic value this study brings as it reinforces BioStem's position as a leader in providing effective evidence based solutions for chronic wound care. Speaker 200:14:54We remain optimistic that the current proposed LCD will not get implemented in 2025 without amendments being implemented, which could favor BioStem. Looking forward, we're confident that these trials will provide additional clinical validation for our commercial products, efficacy, driving expanded payer coverage and broader adoption of BioSymes allografts. Pivoting to the equity capital markets front, we made a significant advancement in September by filing a Form 10 with the SEC on 27th and simultaneously submitting our NASDAQ uplisting application. We are now working through our initial SEC review comments and plan to submit a formal response along with an amended Form 10 in Q4. This uplifting to a national exchange and transition to fully reporting status are key milestones in BioSom's strategy aimed at enhancing our credibility, broadening our investor reach and increasing access to capital, essential drivers of a long term shareholder value as we continue to execute on our growth initiatives. Speaker 200:15:55In closing, as we enter the Q4, we remain optimistic about BioSyn's continued growth and the significant milestones on the horizon. With the recent nationwide launch of Bendaj AC and established reimbursement across all MAC regions, we're well positioned to see strong revenue contributions from this product. This quarter marks our 3rd consecutive record of growth and we're excited about the initiatives underway that have the potential to diversify and expand our product offerings. As we continue to advance our strategic priorities, we're confident that BioSim is on a strong trajectory to deliver value to our shareholders, expand our market presence and improve patient outcomes with innovative solutions. We look forward to keeping you up to date on our progress and I appreciate your continued support as we work towards greater success. Speaker 200:16:43Thank you. And we'll now open the call for questions. Operator00:17:12Your first question comes from the line of Kevin Bennett, an individual investor. Speaker 400:17:19Good evening, guys. Good job on the quarter there. Just had a few questions, I guess. The distribution cost maybe is like my biggest thing that I have. I don't know if we could restructure that, maybe give them like an exclusive deal with us or something, maybe more profit for us and then give them a security of having all of our business. Speaker 400:17:432nd question is the I'm assuming this is like a cream that you put on diabetic wounds. Is it actually possible to have this like an airborne, like spray thing, like burn victims? Would that actually work on a product like that? And then my third question is on the uplifting, the share structure, what will happen with the share structure? I know we're like at about $16,000,000 $11,000,000 out $5,000,000 restricted. Speaker 400:18:14Just curious what will happen with that. Like I say, that's all the questions I have. I appreciate your work. Speaker 200:18:23Thanks, Kevin, for being a long term shareholder and really appreciate the questions. 1st and foremost on the distribution side with Venture Medical, right now we're continuing to kind of work through that team and they've done an amazing job of expanding access to our product across all the MAC regions. I think right now we're looking at continuing that type of relationship in the near term. And to kind of compare it to, I guess, maybe competitors, if we were to internalize this type of sales force from a W2 perspective, I think we would see similar costs associated with this marketplace in getting product out into the marketplace. On the second question in regards to a cream, actually our products are considered what they call tissue allografts. Speaker 200:19:14So we actually harvest a piece of tissue off of the placenta. And so it's like a sheet like format that's laid into the wound bed across the wound and it acts as a barrier or cover for these chronic type wounds, so diabetic foot ulcers, pressure ulcers and venous leg ulcers? And then 3rd, in regards to the capital structure excuse me, the equity capital structure, right now, I believe there's about 16 and so 1,000,000 shares outstanding in common stock. That would be kind of ultimately move from OTC up to NASDAQ. And then any of the warrants and options that are outstanding would also move up to NASDAQ. Speaker 200:19:59So currently, that's kind of the plan with the direct listing. Speaker 400:20:06Okay. Thanks a lot. Speaker 200:20:08No problem, sir. Operator00:20:17Your next question comes from the line of Paige Taggart with APT Capital. Hey, Jason, congrats on another record quarter. Just a quick question, if you could provide some more color around distribution channel with Venture Medical, I guess specifically the sales cycle would be helpful for me. Thanks. Speaker 200:20:39Yes. Thanks, Dave. So just kind of get a little bit more color to kind of how we fulfill and manage the pipeline with Venture Medical. So Venture Medical on a daily basis is ordering product from us and we are shipping it out on a daily basis. It's very lean and FIFO type arrangement with that organization. Speaker 200:21:02And then secondly, they're continuing to have weekly conversations with us about what is the demand pipeline looking like and we're continuing to kind of monitor from a manufacturing perspective how quickly we need to increase production in specific sizes and that's associated with their robust platform called Venture 1View that they utilize with their downstream customers to ultimately kind of see where these types of wounds are going. In this process, typically these wounds or these providers ultimately run what's called an IVR, insurance verification request, And they can see kind of where and what size the wound is and can kind of get an idea of, okay, where is the wound going from an initial size and then kind of as the wound gets closer to closure. So that allows us to have a little bit more insight on product needs and kind of product production. So thanks for your question. Operator00:22:04Thank you. Your next question comes from the line of Ernest Watts with Watts Associates. Speaker 500:22:14I appreciate the progress that you're showing and the comments that you made today. You mentioned in the release that build up costs were significant and apparently much more significant than the Q2. Could you give a comment on roughly what they were in each of the 2 quarters, please? Speaker 200:22:39Ernest, could you clarify your question a little bit? When you say build up costs, what do you mean? Speaker 500:22:46It costs money to get your product out into the field and you have to have people to do that, those people are hired before the actual revenues come in. So I'm referring to costs that precede revenues. Speaker 200:23:09Got it. So, yes, as mentioned on the income statement, notice there's obviously elements of SG and A. Obviously, the biggest one is bona fide services. Those services are specific to Venture Medical being out into the field and commercializing our product. And those are a direct correlation to the revenue, top line revenues specifically. Speaker 200:23:34So as top line revenue increases, those specific bonafide services, which make up a large portion of the SG and A, kind of incrementally shift in that direction. Speaker 500:23:48Could you give a rough figure for the 2 each of the 2 quarters? Speaker 300:23:58Go ahead, I can help with that, Jason, if you want. So sales and marketing so Bonafide service fees are included in sales and marketing expenses for a few for Q3, they were $65,100,000 for 3 months. And for the previous quarter, I want to say they were around 50, around mid-50s, dollars 50 something million. And again, that's indirect. Those costs go up or down with in relation to revenue. Speaker 300:24:24So as revenue increases, you can expect those bonafide service fees and sales and marketing expenses to go up. Does that help? Speaker 100:24:36That's it. Speaker 500:24:38Okay. Thank you Speaker 200:24:40for your questions. Operator00:24:46I will now turn the call back over to Jason Monachevsky for closing remarks. Speaker 200:24:52Well, thanks everyone for joining the call today. We had an amazing Q3 results And I want to thank everybody, specifically all of the BioSEM team members as well as the folks at Venture Medical for all the amazing success that we've had in Q3 of this year and looking forward to sharing our results for the end of the year and Q4 results with you all in the near term. Thank you everyone and have a great night. Operator00:25:19Ladies and gentlemen, that concludes today's call. Thank you all for joining. You may now disconnect.Read morePowered by